HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY
Matthieu Allez 1
James D. Lewis 2
Peter Irving 3
Timothy Hoops 4
James Izanec 4
Tony Ma 5
Zhijie Ding
Erik Muser
Christopher Gasink
Remo Panaccione
Edward V. Loftus Jr
Bruce E. Sands
Silvio Danese
1 Université de Paris,Paris,France
2 Perelman School of Medicine at the University of Pennsylvania,Philadelphia,United States
3 Guy’s and Saint Thomas’ Hospitals NHS Trust,London,United Kingdom
4 Janssen Scientific Affairs, LLC,Horsham,United States
5 Janssen Scientific Affairs, LLC,Hor
Session
IBD: Clinical trials III
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]